This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
It is the first hospital in the country to achieve the significant milestone of completing over 2600 robotic surgeries for treating patients with prostate, kidney and urinary bladder cancer
It affects up to 10 per cent of women of reproductive age around the world
Subscribe To Our Newsletter & Stay Updated
